Download
13019_2024_Article_3326.pdf 1,23MB
WeightNameValue
1000 Titel
  • Direct-acting oral anticoagulant removal by intraoperative hemoadsorption in CABG and/or single valve surgery: interim analysis of the International Safe and Timely Antithrombotic Removal (STAR) registry
1000 Autor/in
  1. Schmoeckel, Michael |
  2. Thielmann, Matthias |
  3. Vitanova, Keti |
  4. Eberle, Thomas |
  5. Marczin, Nandor |
  6. Hassan, Kambiz |
  7. Liebold, Andreas |
  8. Lindstedt, Sandra |
  9. Mächler, Georg |
  10. Matejic-Spasic, Marijana |
  11. Wendt, Daniel |
  12. Deliargyris, Efthymios N. |
  13. Storey, Robert F. |
1000 Verlag BioMed Central
1000 Erscheinungsjahr 2025
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2025-01-20
1000 Erschienen in
1000 Quellenangabe
  • 20(1):74
1000 Copyrightjahr
  • 2025
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s13019-024-03326-1 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749377/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Objective!#!Patients on direct-acting oral anticoagulants (DOACs) are at high risk of perioperative bleeding complications. Intraoperative hemoadsorption is a novel strategy to reduce perioperative bleeding in patients on DOACs undergoing non-deferable cardiac surgery. The international STAR-registry reports real-world clinical outcomes associated with this application.!##!Methods!#!The hemoadsorption device was incorporated into the cardiopulmonary bypass (CPB) circuit and active for the duration of the pump run. Patients on DOACs undergoing CABG and/or single valve surgery before completing the recommended washout were included. Outcome measurements included bleeding events according to standardized definitions and 24-hour chest-tube-drainage (CTD).!##!Results!#!A total of 62 patients were included from 7 institutions in Austria, Germany, Sweden, and the UK (mean age 69.9 ± 7.5years, 71% male). Approximately half were on apixaban and the other half was split between rivaroxaban and edoxaban with 21% of patients also on aspirin. Surgery occurred at a median time of 28.9 h since the last DOAC dose with single valve surgery accounting for 2/3 of cases. Mean CPB duration was 118.6 ± 46.4 min. Severe bleeding (UDPB ≥ 3) occurred in 4.8%, and BARC-4 bleeding occurred in 3.2% of the patients. Only one patient (1.6%) required reoperation for bleeding control. The mean 24-hour CTD was 771.3 ± 482.79mL. No device-related adverse events were reported.!##!Conclusions!#!This interim report of the ongoing STAR-registry shows that, in patients on DOAC undergoing non-deferable CABG and/or single valve surgery, the use of intraoperative hemoadsorption is associated with low rates of severe perioperative bleeding complications. Further prospective studies in larger cohorts are needed to validate the efficacy of this method.!##!Clinical registration number!#!ClinicalTrials.gov identifier: NCT05077124.
1000 Sacherschließung
lokal Antithrombotic removal
lokal Female [MeSH]
lokal Coronary Artery Bypass/adverse effects [MeSH]
lokal Anticoagulants/adverse effects [MeSH]
lokal Anticoagulants/administration
lokal Aged [MeSH]
lokal Humans [MeSH]
lokal Middle Aged [MeSH]
lokal Time Factors [MeSH]
lokal Administration, Oral [MeSH]
lokal Blood Loss, Surgical/prevention
lokal DOAC
lokal CytoSorb
lokal Postoperative Hemorrhage/prevention
lokal Male [MeSH]
lokal Research
lokal Cardiac surgery
lokal Coronary Artery Bypass/methods [MeSH]
lokal Hemoadsorption
lokal Registries [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/U2NobW9lY2tlbCwgTWljaGFlbA==|https://frl.publisso.de/adhoc/uri/VGhpZWxtYW5uLCBNYXR0aGlhcw==|https://frl.publisso.de/adhoc/uri/Vml0YW5vdmEsIEtldGk=|https://frl.publisso.de/adhoc/uri/RWJlcmxlLCBUaG9tYXM=|https://frl.publisso.de/adhoc/uri/TWFyY3ppbiwgTmFuZG9y|https://frl.publisso.de/adhoc/uri/SGFzc2FuLCBLYW1iaXo=|https://frl.publisso.de/adhoc/uri/TGllYm9sZCwgQW5kcmVhcw==|https://frl.publisso.de/adhoc/uri/TGluZHN0ZWR0LCBTYW5kcmE=|https://frl.publisso.de/adhoc/uri/TcOkY2hsZXIsIEdlb3Jn|https://frl.publisso.de/adhoc/uri/TWF0ZWppYy1TcGFzaWMsIE1hcmlqYW5h|https://frl.publisso.de/adhoc/uri/V2VuZHQsIERhbmllbA==|https://frl.publisso.de/adhoc/uri/RGVsaWFyZ3lyaXMsIEVmdGh5bWlvcyBOLg==|https://frl.publisso.de/adhoc/uri/U3RvcmV5LCBSb2JlcnQgRi4=
1000 Hinweis
  • DeepGreen-ID: bedf276645204498817fa8aabf83da79 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. CytoSorbents Inc., Princeton, NJ, USA |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer CytoSorbents Inc., Princeton, NJ, USA |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6502365.rdf
1000 Erstellt am 2025-02-05T16:30:20.629+0100
1000 Erstellt von 322
1000 beschreibt frl:6502365
1000 Zuletzt bearbeitet 2025-09-14T11:35:46.256+0200
1000 Objekt bearb. Sun Sep 14 11:35:46 CEST 2025
1000 Vgl. frl:6502365
1000 Oai Id
  1. oai:frl.publisso.de:frl:6502365 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source